Novavax cuts 2024 revenue forecast
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its Covid-19 and influenza combination vaccine (CIC) and standalone influenza vaccines after a month-long clinical hold. The FDA initially ...
Shares of Novavax Inc. NVAX rose 1.39% to $7.32 Friday, on what proved to be an all-around rough trading session for the ...
Stock analysts at HC Wainwright issued their Q3 2024 earnings estimates for shares of Novavax in a note issued to investors ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today ...
Novavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $7.76 which represents a decrease of $-0.70 or -8.27% from the prior close of $8.46. The stock opened at $8.44 and touched a low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback